LeonaBio Accelerates ELAINE‑3 Trial to Offer New Hope for Metastatic Breast Cancer
LeonaBio’s Phase 3 ELAINE‑3 trial seeks to expand treatment options for ER+ HER2‑negative metastatic breast cancer, combining Lasofoxifene with abemaciclib and aiming for 600 patients to boost statistical power.
2 minutes to read